Junior Healthcare Company (OTCBB: OXIS) Vitalizes Marketing Efforts as Product Launch Commences

Atlanta, GA 4/18/12 (StreetBeat) -- Getting market exposure is one of the greatest challenges of any company on a limited budget. It’s truly a double-edge sword for small cap companies as a basic matter of economics. It takes revenue to support a marketing campaign, but it takes the marketing and sales team to generate revenue. Micro-caps are unfortunately left with few options that aren’t antagonistic towards many shareholders because of dilutive practices or financing that can damage share value. But, make no bones about it, marketing budgets are important because sales can beget more sales. If the company has a good product, it will pay dividends and be money well spent.

OXIS International, Inc. (OTCBB:OXIS), a Beverly Hills, California-based company, develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT™ (99% pure L-ergothioneine), known as the intelligent antioxidant. With a proven safety profile, EGT has been nicknamed the “intelligent antioxidant,” EGT is regarded as the only antioxidant with a transport mechanism to deliver it through cell membranes and the mitochondria, or energy producing part of a cell. OXIS holds the exclusive patent to manufacture EGT.

The OXIS product line is focused on counteracting oxidative stress, an imbalance between the production of reactive oxygen and the body’s ability to readily detoxify the reactive intermediates or easily repair the resulting damage. The company has a broad portfolio of products that range from therapeutic nutraceutical products, cosmeceutical products and proprietary formulations to clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.

Today, the company reported taking a large step forward in its marketing efforts as it launches its line of EGT™-based products with the retention of BDR, a premium marketing solution company. If you’re wondering, BDR is “Brand+Direct Response”. A specialist in display media strategy, BDR partners with most of comScore's top 1000 for the cutting-edge of display marketing capabilities.

According to the news today, “BDR will promote, market and create a full digital advertising campaign for the line of health and nutrition products, reaching a targeted audience of more than 109 million through its BDR advertising network and through mobile and video advertising.”

First-up on the commercialization block is OXIS’s ErgoFlex™, a unique, clinically-proven dietary supplement for the rapid relief of joint pain and improved mobility. ErgoFlex™ was successfully test marketed in a direct mail campaign by OXIS in 2011. Additional products are expected to launch in early summer.

A thinly-traded stock, shares of OXIS have slid from highs of 61 cents in late 2009 to an area just over 2 cents recently. The last time shares dipped this low in 2008 was the beginning of a 13-month climb to those old highs; making the chart effectively what could be called a very large “double bottom” pattern. Today’s trading has given shares a 40 percent boost in price to 3.5 cents each, but still means that the company only commands a market cap of just over $8 million. OXIS has some cash in hand to kick-start its marketing efforts as it has received a $500,000 equity investment and a commitment for an additional $500,000 in working capital to support the product launch. Investors will have their eyes open for news of the coffers starting to be lined up as commercialization is underway to bolster share value and, subsequently, the market cap. Proper due diligence is, as always, encouraged.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly